C difficile risk
Oral Bioavailability


1g IV q24h

eGFR 0- 30eGFR > 30500mg IV q24h1g IV q24h

500mg IV daily

For hemodialysis, give dose after dialysis on HD days

General Information

Targeted therapy of ESBL infections and other resistant gram negative infections.

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

  • Seizure risk lower than other carbapenems

Carbapenems may cause rapid and profound decrease in valproic acid levels. Increasing valproic acid dosage is often NOT sufficient to overcome this interaction. Avoid this combination if at all possible.

IV Administration

  • NS only (incompatible with D5W).

  • Dilute in 50mL NS, infuse over 30 min.

EH Prescribing Restrictions

  • None

  • Pharmacist review of therapy

Community IV Formulary (Metro Region)

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 4 hours

Biliary penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic